Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma

Completed · Phase 2

Conditions studied: Sarcoma

In brief

RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase II trial is studying how well imatinib mesylate works in treating patients with HIV-related Kaposi's sarcoma.

Key facts

Study ID
NCT00090987
Run by
AIDS Malignancy Consortium
People needed
30
Starts
2005-06-01
Expected to finish
2009-12-01
Last updated by the study team
2018-06-06

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.